目的 评价观察化疗联合胸腺肽α1对乳腺癌患者毒副作用及免疫功能的影响.方法 87例乳腺癌患者随机分为治疗组43例和对照组44例.对照组单用化疗.治疗组采用胸腺肽α1+化疗,胸腺肽α1给药方案:化疗当天开始1.6 ms/周,皮下注射,直至患者完成2个疗程的化疗.结果 2组均按期完成化疗计划.化疗期间,治疗组19例,对照组有31例WBC<4×10~9/L.2组WBC<4×10~9/L患者的例数差异有统计学意义(χ~2=6.14,P<0.05).对照组有26例患者,治疗组有34例出现胃肠道不良反应.2组胃肠道不良反应发生率差异有统计学意义(χ~2=4.06,P<0.05).治疗组化疗后细胞免疫指标水平高于对照组,差异有统计学意义(P<0.05或P<0.01).结论 胸腺肽α1配合化疗能提高患者的免疫功能,改善患者生活质量.%Objective To evaluate the impact of the thymosin alpha 1 on the toxicity and cellular immune function during chemotherapeutic treatment of breast cancer. Methods Eighty-seven patients of breast cancer were randomly divided into two groups: study group (chemotherapy of CAF combined with thymosin alpha 1) and control group(chemotherapy of CAF alone). The patients were given thyrnosin alpha 1 at the dose of 1.6 mg per week and at the end of 2 periods of chemotherapy. Results Rates of gastrointestinal upset and bone marrow depression in study group were significantly lower than those in control group(P<0.05). The levels of CD3, CD4, CD4/CD8, IL-2 and IL-12 of patients in study group were significantly higher than those of control group after chemotherapy (P<0.05). Conclusion The combination of thymosin alpha 1 and chemotherapy for the treatment of breast cancer can enhance cellular immune function and improve the quality of breast cancer patient's life.
展开▼
